Latest Conference Content

A day after House Republicans voted to pass legislation that repeals and replaces large parts of the Affordable Care Act, Avik Roy, Forbes opinion editor and president of the Foundation for Research on Equal Opportunity, outlined what Republicans are trying to fix. After his presentation, he joined a panel discussion on what impact the American Health Care Act will have.

At the ACO & Emerging Healthcare Delivery Coalition®, people from around the country who are successfully creating new ways to deliver value-based care come together to share learnings and best practices for attendees to take back to the office on Monday, explained Clifford Goodman, PhD, moderator at the ACO Coalition spring live meeting in Scottsdale, Arizona, and senior vice president and director at the Center for Comparative Effectiveness Research at the Lewin Group.

Healthcare organizations really need to be careful that the protected health information flow is safe and there are no vulnerable spots where that information can be accessed and cause a HIPAA violation, explained Lee Barrett, executive director of the Electronic Healthcare Network Accreditation Commission.

The current form of the American Health Care Act would greatly impact patients in New Orleans, where a high percentage of people have chronic diseases that count as preexisting conditions, explained Michael Griffin, president and CEO of Daughters of Charity Services.

Although Daniel George, MD, of the Duke Cancer Institute, sees value in cancer vaccines and expects they will start showing more benefit to patients, he acknowledges that a barrier to widespread use of cancer vaccines is that they don't show an immediate response.

Negotiations among House Republicans have led to a compromise that would amend the American Health Care Act and the Association of Community Cancer Centers (ACCC) is concerned the amendment would undermine patient protections that are important for people with cancer, said Leah Ralph, director of health Policy at ACCC.

When the COA Patient Advocacy Network converged on Capitol Hill on April 26, 50 advocates were able to discuss their concerns with a number of issues facing patients with cancer, including 340B and clinic consolidation, explained Rose Gerber, director of patient advocacy for the Community Oncology Alliance (COA).

The first drugs for nonalcoholic steatohepatitis (NASH) won't be approved until 2019 at the earliest, but with 16 million Americans affected and another 6 million to 10 million at high risk, the market could be expensive and it's worth keeping an eye on, said Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.

As the use of e-prescribing expands, it will begin to encompass more than just writing an initial prescription to include many interactions between healthcare providers, according to Doug Hillblom, PharmD, president at Arena Healthcare, LLC.

Richard J. Willke, PhD, chief science officer of ISPOR, previews the discussions at the ISPOR 22nd Annual International Meeting, which will be held May 20-24 in Boston, Massachusetts, including topics on the future of health policy in the United States and social networking interventions.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo